RenovoRx Q2 net loss holds at $2.91 million; revenue more than doubled to $909,000 year over year
Reuters2026/08/12 20:07- RenovoRx posted Q2 revenue of USD 909,000, up 61% sequentially, with gross margin of about 84%.
- Net loss was USD 2.9 million, little changed year over year; loss per share narrowed to USD 0.06.
- SG&A climbed to USD 2.9 million; R&D eased to USD 1.2 million.
- Raised 2026 revenue guidance to USD 3.75 million-USD 4.25 million, citing accelerating commercial adoption and repeat ordering.
- Ended Q2 with 21 active commercial cancer centers; Phase III TIGeR-PaC trial reached full enrollment, with topline data expected in H2 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Stellar network stablecoin transfer volume increases by 50%, supply decreases by 11.7%
The U.S. Treasury market remains overheated! Besent expands repo program, emphasizing "this is not quantitative easing"
U.S. Treasury Secretary Janet Yellen stated on Tuesday that the Treasury's decision last month to expand the buyback program for older-dated U.S. Treasury bonds was mainly aimed at "cooling down" the bond market, which has been heating up recently, and helping the market return to a more balanced state.
Lupatech ratifies Mipel’s BRL 1.59 million private commercial note issuance
Crypto prices
More
